Want to see IN:SMSPHARMA full AI Analyst Report?
SMSPHARMA Stock Chart & Stats
₹325.40
-₹5.32(-2.16%)
At close: 4:00 PM EST
₹325.40
-₹5.32(-2.16%)
Day’s Range― - ―
52-Week Range₹208.20 - ₹446.50
Previous CloseN/A
Volume71.57K
Average Volume (3M)105.50K
Market Cap
₹36.33B
Enterprise Value₹38.40B
Total Cash (Recent Filing)₹460.75M
Total Debt (Recent Filing)₹3.65B
Price to Earnings (P/E)34.1
Beta1.65
Next Earnings
Aug 10, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.1%
Share Statistics
EPS (TTM)11.32
Shares Outstanding93,652,030
10 Day Avg. Volume15,241
30 Day Avg. Volume105,503
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)4.36
Price to Sales (P/S)3.87
P/FCF Ratio-37.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Profitability And Revenue TrendReturn to solid profits across FY2024–FY2026 alongside positive revenue growth demonstrates the company has restored core operating economics. This durable improvement increases internal funding capacity, supports reinvestment in capacity and compliance, and reduces reliance on external financing in normal cycles.
Improving Leverage And Stronger Capital BaseDeclining total debt and a larger equity base materially improve financial flexibility and solvency headroom. A stronger balance sheet supports capex and working-capital needs, lowers refinancing risk, and provides capacity to weather industry cycles or pursue targeted capacity investments over the coming months.
Stable B2B API Manufacturing Business ModelA focused API/intermediate manufacturing model serving domestic and export formulators yields repeat B2B demand and diversified end markets. Specialized manufacturing, regulatory approvals and scale create entry barriers, supporting steady volume-based revenue and long-term customer relationships.
Bears Say
Recurring Negative Free Cash FlowPersistent negative free cash flow, and a sharp FY2026 deterioration, constrains the firm's ability to self-fund capex, dividends or debt reduction. Over several months this raises dependence on external financing, increases liquidity risk and weakens the durability of reported earnings.
Weak Operating Cash ConversionOperating cash flow that is modest relative to reported profits signals low cash conversion and raises earnings-quality concerns. If profits do not translate into cash, the company may struggle to fund working capital, capex or repay debt without tapping markets, reducing financial resilience.
Margin Volatility And Uneven EarningsSignificant gross-margin compression and an earlier loss year indicate uneven earnings power and sensitivity to input costs or pricing. Such variability reduces predictability of cash flows, complicates capacity planning and heightens vulnerability to competitive or raw-material shocks over the medium term.
SMS Pharmaceuticals Limited News
SMSPHARMA FAQ
What was SMS Pharmaceuticals Limited’s price range in the past 12 months?
SMS Pharmaceuticals Limited lowest stock price was ₹208.20 and its highest was ₹446.50 in the past 12 months.
What is SMS Pharmaceuticals Limited’s market cap?
SMS Pharmaceuticals Limited’s market cap is ₹36.33B.
When is SMS Pharmaceuticals Limited’s upcoming earnings report date?
SMS Pharmaceuticals Limited’s upcoming earnings report date is Aug 10, 2026 which is in 18 days.
How were SMS Pharmaceuticals Limited’s earnings last quarter?
SMS Pharmaceuticals Limited released its earnings results on May 22, 2026. The company reported ₹3.58 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.58.
Is SMS Pharmaceuticals Limited overvalued?
According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Overvalued.
Does SMS Pharmaceuticals Limited pay dividends?
SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.1%. See more information on SMS Pharmaceuticals Limited dividends here
What is SMS Pharmaceuticals Limited’s EPS estimate?
SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Pharmaceuticals Limited have?
SMS Pharmaceuticals Limited has 93,652,030 shares outstanding.
What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?
SMS Pharmaceuticals Limited reported an EPS of ₹3.58 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10.537%.
Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:SMSPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of APIs targeting various therapeutic categories, including anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral applications. Furthermore, SMS Pharmaceuticals engages in contract research activities and exports its products globally.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Senores Pharmaceuticals Ltd.
―